文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

在非小细胞肺癌(NSCLC)患者中,在放疗前和放疗期间同时进行¹⁸F-氟代脱氧葡萄糖(FDG)代谢、¹⁸F-氟代胸腺嘧啶(FLT)增殖和¹⁸F- 米妥唑胺(F-miso)缺氧的正电子发射断层扫描(PET)评估:一项初步研究。

Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.

机构信息

Department of Nuclear Medicine, Henri Becquerel Cancer Center and Rouen University Hospital, France.

出版信息

Radiother Oncol. 2011 Jan;98(1):109-16. doi: 10.1016/j.radonc.2010.10.011. Epub 2010 Nov 4.


DOI:10.1016/j.radonc.2010.10.011
PMID:21056487
Abstract

OBJECTIVES: To investigate the changes in tumour proliferation (using FLT), metabolism (using FDG), and hypoxia (using F-miso) during curative (chemo-) radiotherapy (RT) in patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Thirty PET scans were performed in five patients (4 males, 1 female) that had histological proof of NSCLC and were candidates for curative-intent RT. Three PET-CT (Biograph S16, Siemens) scans were performed before (t(0)) and during (around dose 46 Gy, t(46)) RT with minimal intervals of 48 h between each PET-CT scan. The tracers used were (18)fluoro-2deoxyglucose (FDG) for metabolism, (18)fluorothymidine (FLT) for proliferation, and (18)F-misonidasole (F-miso) for hypoxia. The 3 image sets obtained at each time point were co-registered (rigid: n=9, elastic: n=1, Leonardo, TrueD, Siemens) using FDG PET-CT as reference. VOIs were delineated (40% SUV(max) values were used as a threshold) for tumours and lymph nodes on FDG PET-CT, and they were automatically pasted on FLT and F-miso PET-CT images. ANOVA and correlation analyses were used for comparison of SUV(max) values. RESULTS: Four tumours and twelve nodes were identified on initial FDG PET-CT images. FLT SUV(max) values were significantly lower (p<0.0006) at t(46) in both tumours and nodes. The decrease in FDG SUV(max) values had a trend towards significance (p=0.048). F-Miso SUV(max) values were significantly higher in tumours than in nodes (p=0.02) and did not change during radiotherapy (p=0.39). A significant correlation was observed between FLT and FDG uptake (r=0.56, p<10(-4)) when all data were pooled together, and they remained similar when the before and during RT data were analysed separately. FDG and F-miso uptakes were significantly correlated (r=0.59, p=0.0004) when all data were analysed together. The best fit was obtained after adjusting for lesion type (tumour vs. node). This correlation was observed for the SUV(max) measured during RT (r=0.70, p=0.008) but not for the pre-RT data (r=0.19, p=0.35). The weak correlation between FLT and F-miso uptakes only became significant (r=0.66, p=0.002) when the analysis was restricted to the data acquired during RT. CONCLUSION: Three different PET acquisitions can be performed quasi-simultaneously (4-7 days) before and during radiotherapy in patients with NSCLC. Our results at 46 Gy suggest that a fast decrease in the proliferation of both tumours and nodes exists during radiotherapy with differences in metabolism (borderline significant decrease) and hypoxia (stable).

摘要

目的:研究非小细胞肺癌 (NSCLC) 患者在接受根治性(化疗)放疗 (RT) 过程中肿瘤增殖(使用 FLT)、代谢(使用 FDG)和缺氧(使用 F-miso)的变化。 方法:对 5 名经组织学证实患有 NSCLC 且有根治性意向 RT 适应证的患者进行了 30 次 PET 扫描。在 RT 期间(约 46 Gy 时,t(46)) 进行了 3 次 PET-CT(Biograph S16,西门子)扫描,每次 PET-CT 扫描之间的间隔最小为 48 小时。使用的示踪剂包括代谢用 (18)氟-2-脱氧葡萄糖 (FDG)、增殖用 (18)氟胸腺嘧啶 (FLT) 和缺氧用 (18)氟米索硝唑 (F-miso)。使用 FDG PET-CT 作为参考,使用 (18)FLT 和 F-miso PET-CT 图像对每个时间点获得的 3 个图像集进行刚性(n=9)和弹性(n=1,Leonardo、TrueD、西门子)配准。在 FDG PET-CT 上为肿瘤和淋巴结勾画 VOI(使用 40% SUV(max) 值作为阈值),并自动将其粘贴到 FLT 和 F-miso PET-CT 图像上。使用 ANOVA 和相关性分析比较 SUV(max) 值。 结果:在初始 FDG PET-CT 图像上识别出 4 个肿瘤和 12 个淋巴结。在 t(46) 时,肿瘤和淋巴结的 FLT SUV(max) 值均显著降低(p<0.0006)。FDG SUV(max) 值的降低有统计学意义(p=0.048)。肿瘤的 F-Miso SUV(max) 值明显高于淋巴结(p=0.02),且在放疗期间无变化(p=0.39)。当所有数据汇总在一起时,FLT 和 FDG 摄取之间观察到显著相关性(r=0.56,p<10(-4)),当分别分析 RT 前后的数据时,相关性仍相似。FDG 和 F-miso 摄取之间存在显著相关性(r=0.59,p=0.0004),当所有数据一起分析时。最佳拟合是在调整病变类型(肿瘤与淋巴结)后获得的。这种相关性在 RT 期间测量的 SUV(max) 时观察到(r=0.70,p=0.008),但在 RT 前数据中观察不到(r=0.19,p=0.35)。FLT 和 F-miso 摄取之间的弱相关性仅在限制为 RT 期间获得的数据时才变得显著(r=0.66,p=0.002)。 结论:在 NSCLC 患者中,在放疗前和放疗期间可以近乎同时进行三次不同的 PET 采集(4-7 天)。我们在 46 Gy 时的结果表明,肿瘤和淋巴结的增殖在放疗期间迅速下降(存在差异,代谢(有边缘显著下降)和缺氧(稳定)。

相似文献

[1]
Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.

Radiother Oncol. 2010-11-4

[2]
Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).

Radiother Oncol. 2011-8-30

[3]
Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.

Int J Radiat Oncol Biol Phys. 2009-11-15

[4]
FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer.

Radiat Oncol. 2018-10-23

[5]
Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.

J Nucl Med. 2013-8-5

[6]
Comparison of Hypermetabolic and Hypoxic Volumes Delineated on [F]FDG and [F]Fluoromisonidazole PET/CT in Non-small-cell Lung Cancer Patients.

Mol Imaging Biol. 2020-6

[7]
Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?

J Oral Maxillofac Surg. 2015-7

[8]
Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone.

Eur J Nucl Med Mol Imaging. 2014-4

[9]
Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.

J Nucl Med. 2014-5-15

[10]
Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.

J Nucl Med. 2011-11-7

引用本文的文献

[1]
Hypoxia Imaging in Lung Cancer: A PET-Based Narrative Review for Clinicians and Researchers.

Pharmaceuticals (Basel). 2025-3-25

[2]
3'-deoxy-3'-F-fluorothymidine PET imaging of lymphoid tissues in patients with advanced non-small cell lung cancer undergoing anti-programmed cell death-1 therapy.

EJNMMI Res. 2025-4-1

[3]
A Review of Hypoxia Imaging Using 18F-Fluoromisonidazole Positron Emission Tomography.

Methods Mol Biol. 2024

[4]
Plasma Lipidomics Profiling to Identify the Biomarkers of Diagnosis and Radiotherapy Response for Advanced Non-Small-Cell Lung Cancer Patients.

J Lipids. 2024-1-27

[5]
Positron Emission Tomography (PET)/Computed Tomography (CT) Imaging in Radiation Therapy Treatment Planning: A Review of PET Imaging Tracers and Methods to Incorporate PET/CT.

Adv Radiat Oncol. 2023-3-27

[6]
The lung cancers: staging and response, CT, F-FDG PET/CT, MRI, DWI: review and new perspectives.

Br J Radiol. 2023-8

[7]
Advances in PET and MRI imaging of tumor hypoxia.

Front Med (Lausanne). 2023-2-9

[8]
Timing of hypoxia PET/CT imaging after 18F-fluoromisonidazole injection in non-small cell lung cancer patients.

Sci Rep. 2022-12-16

[9]
3'-Deoxy-3'-(18F) Fluorothymidine Positron Emission Tomography/Computed Tomography in Non-small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy: A Pilot Study.

Adv Radiat Oncol. 2022-7-26

[10]
F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition.

Clin Cancer Res. 2022-1-15

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索